| Methods | D: crossover C: unclear B: double WD: 5/29 J: 1‐1‐0 DU: 4w/2x8w (4w)/‐ | |
| Participants | N: 29/24 D: 4 migraine with, 25 without aura C: unclear F: 86% A: 24‐47 years DU: 4‐40 years S: private practice, Finland | |
| Interventions | P: 160 mg C: Femoxetine 400 mg | |
| Outcomes | R: 3/11 vs. 1/11 (1st period; no pooled data) F: 1st period: 5.00 (sem 0.71) vs. 6.81 (1.12); pooled: 4.67 (sem 0.64) vs. 6.16 (0.82) AU: propranolol better HI: propranolol significantly better AEs: more side effects with propranolol Dropouts‐AEs: 3/29 vs. 0/29 V: (+) | |
| Notes | Responder data presented only for separate phases; frequency data reported for separate phases and for both phases pooled | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.